Literature DB >> 17381385

Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients.

Rhonda S Rea1, Sarah Battistone, Jeffrey J Fong, John W Devlin.   

Abstract

Delirium is common in acutely ill patients and can result in substantial morbidity if left untreated. Atypical antipsychotics have been postulated to be safer and more effective than haloperidol for treatment of this condition. To evaluate the role of atypical antipsychotics versus haloperidol for treatment of delirium in hospitalized acutely ill adults, we searched MEDLINE (1977-September 2006) and International Pharmaceutical Abstracts (1997-September 2006) for English-language publications of clinical trials that compared atypical antipsychotics and haloperidol. Four comparative studies were identified: one double-blind, randomized study (risperidone vs haloperidol), one single-blind, randomized study (olanzapine vs haloperidol), and two retrospective studies (olanzapine vs haloperidol and quetiapine vs haloperidol). These studies demonstrated that atypical antipsychotics are as efficacious as haloperidol. In addition, they appear to be associated with a lower frequency of extrapyramidal effects, and thus are safer than haloperidol. However, these conclusions are based on a limited number of studies; larger comparative trials are needed to elucidate the role of atypical antipsychotics for treating delirium in this population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17381385     DOI: 10.1592/phco.27.4.588

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  14 in total

Review 1.  Management of delirium in palliative care: a review.

Authors:  Luigi Grassi; Augusto Caraceni; Alex J Mitchell; Maria Giulia Nanni; Maria Alejandra Berardi; Rosangela Caruso; Michelle Riba
Journal:  Curr Psychiatry Rep       Date:  2015-03       Impact factor: 5.285

Review 2.  Acute hyperglycemia associated with short-term use of atypical antipsychotic medications.

Authors:  T Vivian Liao; Stephanie V Phan
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

3.  Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.

Authors:  Andrew J Muzyk; Amber Rayfield; Jane Y Revollo; Heather Heinz; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

4.  Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case.

Authors:  Carla Meyer-Massetti; Simone Vaerini; Alexandra E Rätz Bravo; Christoph R Meier; B Joseph Guglielmo
Journal:  Int J Clin Pharm       Date:  2011-08-02

5.  Development and Implementation of a Multicomponent Protocol to Promote Sleep and Reduce Delirium in a Medical Intensive Care Unit.

Authors:  Adrienne Darby; Kalynn Northam; C Adrian Austin; Lydia Chang; Stacy Campbell-Bright
Journal:  Ann Pharmacother       Date:  2021-09-07       Impact factor: 3.463

Review 6.  Treatment of Delirium During Critical Illness.

Authors:  Niall T Prendergast; Perry J Tiberio; Timothy D Girard
Journal:  Annu Rev Med       Date:  2021-11-09       Impact factor: 16.048

Review 7.  Neurological complications of cardiac surgery.

Authors:  Rebecca F Gottesman; Guy M McKhann; Charles W Hogue
Journal:  Semin Neurol       Date:  2008-12-29       Impact factor: 3.420

8.  Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options.

Authors:  Joseph D Markowitz; Meera Narasimhan
Journal:  Psychiatry (Edgmont)       Date:  2008-10

9.  Quetiapine in refractory hyperactive and mixed intensive care delirium: a case series.

Authors:  Ruth Y Y Wan; Moneesha Kasliwal; Catherine A McKenzie; Nicholas A Barrett
Journal:  Crit Care       Date:  2011-06-28       Impact factor: 9.097

10.  Prevention and Management of Delirium in the Intensive Care Unit.

Authors:  Matthew F Mart; Shawniqua Williams Roberson; Barbara Salas; Pratik P Pandharipande; E Wesley Ely
Journal:  Semin Respir Crit Care Med       Date:  2020-08-03       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.